Document is current
Any future updates will be listed below
-
Authors
Simeoli, C.
Di Paola, N.
Stigliano, A.
Lardo, P.
Kearney, T.
Mezosi, E.
Ghigo, E.
Giordano, R.
Mariash, C. N.
Donegan, D. M.
Feelders, R. A.
Hand, A. L.
Araque, K. A.
Moraitis, A. G. https://orcid.org/0000-0001-5613-505X
Pivonello, R.
-
Funding
Funding for this research was provided by:
Corcept Therapeutics Incorporated
- License Information
-
More Information
Article History
Received: 19 April 2024
Accepted: 9 September 2024
First Online: 21 September 2024
Declarations
:
: CS received occasional consulting honoraria from BresMed and Recordati. NDP, AS, PL, EG, and RG have nothing to declare. TK received other financial or non-financial interests from Corcept Therapeutics. EM was an investigator for a clinical trial of relacorilant for Corcept Therapeutics and served as a speaker for IBSA, Ipsen, Pfizer, Merck, Novartis, and Recordati. CNM received research support from Corcept Therapeutics. DMD participated in an advisory board for Amryt and Corcept Therapeutics. RAF reports research grants from Corcept Therapeutics; has served as a speaker for HRA Pharma; and consulted and served as a speaker for Recordati. ALH is an employee of Corcept Therapeutics and has stock ownership/options in Corcept Therapeutics. AGM and KAA are employees of Corcept Therapeutics. RP has received research funding from Recordati AG., Corcept Therapeutics, StrongbridgeBiopharma, Neurocrine Biosciences; and served as a consultant for Corcept, Therapeutics, Recordati A., Crinetics Pharmaceuticals, H. Lundbeck A/S.
: The relacorilant study was reviewed and approved by the institutional review board (IRB) at each study center and was conducted in accordance with the World Medical Association Declaration of Helsinki and the International Council on Harmonisation Good Clinical Practice guidelines.
: Written informed consent was obtained from each patient prior to participation. Per institutional guidelines, as a retrospective chart review, the surgical study did not require IRB approval. However, written informed consent with respect to the confidentiality of data collection according to the Italian privacy policy was obtained and recorded in each medical chart at the time of coagulation marker evaluation.
